Mednet Logo

Do you continue ADT/Lupron in all patients with castrate resistance prostate cancer?

Are there exceptions?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Michigan
Answered on

It is recommended to continue ADT in patients with castration-resistant prostate cancer. Some mechanisms of castration-resistance include upregulation of androgen receptors and autocrine testosterone production, so a castration-resistant cancer is not necessarily a "hormone resistant" cancer.

Join for free or sign in to see the full answer